More precisely, patients treated with GA, fingolimod, IFN-β, or dimethyl fumarate (DMF) showed a higher number of Breg with a restored production of IL-10 and a shift toward a more anti-inflammatory immune profile compensating the tolerogenic loss in MS [27,62,63]. This evidence concerns the gene IL10 and myeloid sarcoma.